320 related articles for article (PubMed ID: 15530836)
21. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
22. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
24. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
26. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
27. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
29. Current issues in delivering DCs for immunotherapy.
Barratt-Boyes SM; Figdor CG
Cytotherapy; 2004; 6(2):105-10. PubMed ID: 15203986
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell-based immunotherapy.
Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
[TBL] [Abstract][Full Text] [Related]
31. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.
Mossoba ME; Medin JA
Expert Rev Vaccines; 2006 Oct; 5(5):717-32. PubMed ID: 17181444
[TBL] [Abstract][Full Text] [Related]
33. [Immunotherapy: new insights].
Geissler M; Weth R
Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
[TBL] [Abstract][Full Text] [Related]
35. Cell fusion: from hybridoma to dendritic cell-based vaccine.
Gong J; Koido S; Calderwood SK
Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
[TBL] [Abstract][Full Text] [Related]
36. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
Breckpot K; Heirman C; Neyns B; Thielemans K
J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
[TBL] [Abstract][Full Text] [Related]
37. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
38. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro.
Yano Y; Ueda Y; Itoh T; Fuji N; Okugawa K; Naito K; Imura K; Kohara J; Hayashi T; Nakane K; Matsuura Y; Kawai K; Yamagishi H
Oncol Rep; 2006 Jul; 16(1):147-52. PubMed ID: 16786138
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
